RS51854B - Derivati citokina - Google Patents

Derivati citokina

Info

Publication number
RS51854B
RS51854B RS20110103A RSP20110103A RS51854B RS 51854 B RS51854 B RS 51854B RS 20110103 A RS20110103 A RS 20110103A RS P20110103 A RSP20110103 A RS P20110103A RS 51854 B RS51854 B RS 51854B
Authority
RS
Serbia
Prior art keywords
polypeptide
agents
nucleic acid
hiv
host cell
Prior art date
Application number
RS20110103A
Other languages
English (en)
Serbian (sr)
Inventor
Oliver Hartley
Original Assignee
Mintaka Foundation For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mintaka Foundation For Medical Research filed Critical Mintaka Foundation For Medical Research
Publication of RS51854B publication Critical patent/RS51854B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
RS20110103A 2006-07-25 2007-07-25 Derivati citokina RS51854B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
RS51854B true RS51854B (sr) 2012-02-29

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110103A RS51854B (sr) 2006-07-25 2007-07-25 Derivati citokina

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
CN112469429B (zh) * 2018-05-28 2025-02-14 奥立安生物技术瑞士有限责任公司 Ccr5抑制剂在癌症治疗中的应用
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164818C (en) * 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
CA2658806C (en) 2017-01-03
ATE490270T1 (de) 2010-12-15
CN101511867A (zh) 2009-08-19
AU2007278894A1 (en) 2008-01-31
US20090317363A1 (en) 2009-12-24
US20130330305A1 (en) 2013-12-12
JP2009544304A (ja) 2009-12-17
PL2076532T3 (pl) 2011-07-29
SI2076532T1 (sl) 2011-06-30
RU2461567C2 (ru) 2012-09-20
CN101511867B (zh) 2014-04-09
DE602007010969D1 (de) 2011-01-13
RU2009106436A (ru) 2010-08-27
HRP20110146T1 (hr) 2011-06-30
KR20090060281A (ko) 2009-06-11
MX2009000918A (es) 2009-08-26
EP2076532B1 (en) 2010-12-01
HK1131162A1 (en) 2010-01-15
GB0614755D0 (en) 2006-09-06
BRPI0715331B1 (pt) 2021-04-13
WO2008012689A3 (en) 2008-05-08
WO2008012689A2 (en) 2008-01-31
BRPI0715331B8 (pt) 2021-05-25
AU2007278894B2 (en) 2012-08-09
BRPI0715331A2 (pt) 2013-07-16
DK2076532T3 (da) 2011-03-07
CY1111630T1 (el) 2015-10-07
CA2658806A1 (en) 2008-01-31
JP5224603B2 (ja) 2013-07-03
KR101530353B1 (ko) 2015-06-26
ZA200901342B (en) 2010-11-24
PT2076532E (pt) 2011-03-02
ME01320B (me) 2013-12-20
NZ575092A (en) 2011-08-26
EP2076532A2 (en) 2009-07-08
ES2361455T3 (es) 2011-06-17
US9328153B2 (en) 2016-05-03
US8686111B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
US9328153B2 (en) Cytokine derivatives
US6599875B1 (en) IL-6 antagonist peptides
US20060251619A1 (en) Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
CN111840530B (zh) 一种柔嫩艾美耳球虫重组多肽疫苗vnqs的制备及其在抗鸡球虫病中的应用方法
CN103626865B (zh) 具有趋化活性的分泌蛋白及其编码序列和医药用途
HK1131162B (en) Cytokine derivatives
CN111840529B (zh) 一种柔嫩艾美耳球虫重组多肽疫苗vkvq的制备及其在抗鸡球虫病中的应用方法
CN101570760A (zh) 重组鼠β-防御素3多肽及其制备方法与用途
WO2000069910A1 (en) Chemokine-like factors having cell chemokinesis function and proliferation-stimulating activity
KR101138930B1 (ko) Ｈⅰｖ ｎｃ 단백질을 포함하는 ａⅰｄｓ 예방 및 치료용조성물
EP1500662A2 (en) Stabilizing peptides